



RESPONSE TO COMMENT ON JOHNSON ET AL.

Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. *Diabetes Care* 2019;42:69–76

Diabetes Care 2019;42:e79–e80 | <https://doi.org/10.2337/dci19-0010>

Stephanie R. Johnson,^{1,2,3,4}
Hannah E. Carter,⁵ Paul Leo,²
Samantha A. Hollingworth,⁶
Elizabeth A. Davis,^{7,8,9}
Timothy W. Jones,^{7,8,9}
Louise S. Conwell,^{1,4} Mark Harris,^{1,3,4}
Matthew A. Brown,² Nicholas Graves,⁵
and Emma L. Duncan^{2,4,10}

We thank Estrella and Simmons (1) for their letter regarding implications and limitations of our study (2).

We agree that most of the cost and health benefits from identifying maturity-onset diabetes of the young (MODY) mutations in children with diabetes is due to conversion from insulin to oral hypoglycemic agents, as discussed in our article. Further, we agree that conversion is not always possible, although, as illustrated in their case, substantial reduction in dose may be possible even if insulin cannot be ceased entirely. As shown in Table 1 and Fig. 2, our sensitivity analysis tested for uncertainty in conversion rates, varying this parameter from 50% to 100% (based on limited published data); routine testing remained beneficial within this range.

We agree that a limitation of targeted sequencing is an inability to screen genes not included in the target panel.

An alternative would be whole-exome sequencing (WES), which we have demonstrated is sensitive and specific for MODY variant detection (3) and allows future reinterrogation of newly discovered genes. Several recent publications demonstrate improved diagnostic yield from reanalyzing exome data due to improved bioinformatics, updated genetic databases, new literature, and better phenotyping (4,5). Our sensitivity analysis showed cost benefits of routine screening with costs as high as AU\$1,000/test. Although currently more expensive than panel-based approaches, WES costs are rapidly falling; WES may soon prove financially competitive, with added benefits of flexibility and reinterrogation.

Our modeling focused on per-individual cost of genetic testing in children with diabetes and did not include family cascade testing. It is reasonable to expect

that identification of MODY in other family members with diabetes might result in similar clinical benefits (therapeutic change from insulin to sulfonylureas, improved quality of life, etc.). Relevantly, screening for a specific variant usually costs much less than the comprehensive initial screening of a proband.

However, whether cascade testing should be offered to all family members or limited to individuals with hyperglycemia is contentious. The benefit of cascade testing all family members depends in part on penetrance, which (as discussed) is difficult to establish for MODY. For some types of MODY with other clinical features (e.g., *HNF1B*-associated renal tract abnormalities), screening may be relevant even in the absence of diabetes. However, genetic testing of presymptomatic individuals raises the possibility of genetic

¹Department of Endocrinology and Diabetes, Lady Cilento Children's Hospital, South Brisbane, Queensland, Australia

²Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology, Translational Research Institute, Woolloongabba, Queensland, Australia

³University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Woolloongabba, Queensland, Australia

⁴Faculty of Medicine, University of Queensland, Herston, Queensland, Australia

⁵Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia

⁶School of Pharmacy, University of Queensland, Woolloongabba, Queensland, Australia

⁷Department of Diabetes and Endocrinology, Perth Children's Hospital, Perth, Western Australia, Australia

⁸Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia

⁹School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia

¹⁰Department of Endocrinology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

Corresponding author: Emma L. Duncan, emma.duncan@qut.edu.au

S.R.J. and H.E.C. are joint first authors.

© 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

discrimination. In addition, the cost implications of cascade testing will vary from family to family due to varying family size. Thus, modeling costs of cascade testing would be extremely complex and were not included in this study. Similar issues pertain to prenatal testing; this too was not included in our model.

Lastly, the prevalence data for this analysis only included pathogenic/likely pathogenic variants based on American College of Medical Genetics and Genomics criteria (6); variants of uncertain significance were not included. We agree with Estrella and Simmons (1) that pathogenicity of variants—even those previously published as causative in particular families—is difficult to establish definitively (7). This lack of certainty, along with unknown penetrance, has important and time-consuming implications for genetic counseling. Again, these added

complexities were not included in our modeling.

Funding. S.R.J. was supported by a research scholarship from the University of Queensland. M.A.B. is supported by a National Health and Medicine Research Council Senior Principal Research Fellowship.

Duality of Interest. The research was supported by a grant from the Australasian Paediatric Endocrine Care research grant, funded by Pfizer. No other potential conflicts of interest relevant to this article were reported.

References

1. Estrella JFGL, Simmons D. Comment on Johnson et al. Cost-effectiveness analysis of routine screening using massively parallel sequencing for maturity-onset diabetes of the young in a pediatric diabetes cohort: reduced health system costs and improved quality of life. *Diabetes Care* 2019;42:69–76 (Letter). *Diabetes Care* 2019;42:e78. DOI: 10.2337/dc19-0043
2. Johnson SR, Carter HE, Leo P, et al. Cost-effectiveness analysis of routine screening using massively parallel sequencing for maturity-onset diabetes of the young in a pediatric diabetes

cohort: reduced health system costs and improved quality of life. *Diabetes Care* 2019;42:69–76

3. Johnson SR, Leo PJ, McInerney-Leo AM, et al. Whole-exome sequencing for mutation detection in pediatric disorders of insulin secretion: maturity onset diabetes of the young and congenital hyperinsulinism. *Pediatr Diabetes* 2018;19:656–662
4. Wenger AM, Guturu H, Bernstein JA, Bejerano G. Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers. *Genet Med* 2017;19:209–214
5. Al-Nabhani M, Al-Rashdi S, Al-Murshedi F, et al. Reanalysis of exome sequencing data of intellectual disability samples: yields and benefits. *Clin Genet* 2018;94:495–501
6. Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405–424
7. Minikel EV, Vallabh SM, Lek M, et al.; Exome Aggregation Consortium (ExAC). Quantifying prion disease penetrance using large population control cohorts. *Sci Transl Med* 2016;8:322ra9